[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369430-105":59,"doc-detail-369430-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","leucine-rich-repeat-containing-15-promotes-triple-negative-breast-cancer-proliferation-and-invasion-via-the-itgb1fakpi3k-signalling-pathway","Leucine rich repeat containing 15 promotes triple-negative breast cancer proliferation and invasion via the ITGB1/FAK/PI3K signalling pathway","","Leucine rich repeat containing 15 (LRRC15) is studied for its clinical relevance and biological function in triple-negative breast cancer (TNBC). LRRC15 shows robust overexpression in TNBC tissues and cell lines, inversely related to patient survival. Silencing LRRC15 inhibits TNBC proliferation, invasion, and migration in vitro and in vivo. Mechanistically, LRRC15 interacts with ITGB1, promotes ITGB1 phosphorylation, recruits FAK, and activates PI3K/AKT signalling, supporting LRRC15 as a therapeutic target for TNBC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/leucine-rich-repeat-containing-15-promotes-triple-negative-breast-cancer-proliferation-and-invasion-via-the-itgb1fakpi3k-signalling-pathway/369430/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/leucine-rich-repeat-containing-15-promotes-triple-negative-breast-cancer-proliferation-and-invasion-via-the-itgb1fakpi3k-signalling-pathway/369430.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does LRRC15 play in triple-negative breast cancer?","Question",{"text":112,"@type":113},"LRRC15 is highly overexpressed in TNBC and correlates with worse patient outcomes. Functionally, reducing LRRC15 suppresses TNBC cell proliferation, invasion, and migration in vitro and in vivo.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does LRRC15 influence ITGB1 and downstream signalling?",{"text":117,"@type":113},"LRRC15 interacts with ITGB1, facilitates ITGB1 phosphorylation at the T788/T789 residues, and recruits FAK to integrin clusters. This leads to phosphorylation events that activate the PI3K/AKT pathway.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is targeting LRRC15 considered a therapeutic opportunity for TNBC?",{"text":121,"@type":113},"Because LRRC15 promotes TNBC proliferation and metastasis via the ITGB1/FAK/PI3K signalling pathway, it represents a promising candidate for therapeutic intervention aimed at disrupting this pro-tumour signalling axis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369430,1790815159,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nLeucine rich repeat containing 15 promotes triple-negative breast cancer proliferation and invasion via the ITGB1/FAK/PI3K signalling pathway  \nXiao Wu1,2, Yameng Liu2, Yinxi Hu3, Fang Su2, Zishu Wang2, Yongxia Chen2 & Zhixiang Zhuang1􀀍  \nLeucine rich repeat containing 15 (LRRC15) is recognized for its intimate association with the extracellular matrix, where it modulates fibroblast function and shapes the immune landscape within the tumour microenvironment. The specific expression patterns and molecular contributions of LRRC15 in triple-negative breast cancer(TNBC) have not been fully elucidated. This study aimed to delineate the clinical relevance and biological implications of LRRC15 inTNBC, and to assess its potential as a novel therapeutic target for this disease. Our findings revealed robust overexpression of LRRC15 inTNBC tumour tissues and cell lines, which was inversely correlated with patient survival outcomes. Notably, the suppression of LRRC15 expression led to pronounced inhibition ofTNBC cell proliferation, invasion, and migration both in vitro and in vivo. Mechanistically, we established that LRRC15 interacts with Integrin Beta 1(ITGB1), facilitating the phosphorylation oftheT788/T789 residues on ITGB1 and recruiting focal adhesion kinase (FAK) to the site of integrin aggregation. This recruitment promotes the downstream phosphorylation of PI3K andAKT, suggesting that LRRC15 is a key activator of the ITGB1/FAK/PI3K signalling pathway. Collectively, our data indicate that LRRC15 is a critical promoter ofTNBC cell proliferation and metastasis through the activation of this signalling pathway, identifying LRRC15 as a promising candidate for therapeutic intervention inTNBC.  \nKeywords LRRC15, TNBC, ITGB1/FAK/PI3K signalling pathway, Proliferation, Invasion  \nAccording to Global Cancer Statistics, breast cancer is the most common malignancy among women worldwide1. Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases and is distinguished by a higher recurrence rate and a shorter overall survival span than other breast cancer subtypes2. TNBC is characterized by an early age of onset, elevated level of malignancy, and accelerated rate of tumour progression3,4. Unlike luminal breast cancers, which are responsive to endocrine therapies, and HER2-positive tumours that can be targeted with anti-HER2 agents, TNBC is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression5. The molecular profile ofTNBC renders standard endocrine therapies and HER2-targeted treatments ineffective for TNBC, thereby constraining limiting therapeutic options primarily to chemotherapy, surgery, and radiation6,7. This triple-negative phenotype renders TNBC refractory to both hormonal therapies and HER2-directed treatments, constituting a critical unmet clinical need. The aetiology ofTNBC is intricate and involves a complex interplay of molecular mechanisms such as genetic mutations, epigenetic alterations, and the aberrant activation of signalling pathways8,9. There is an imperative need for further in-depth research to unravel the complexities ofTNBC and to devise more effective treatment strategies.  \nLeucine rich repeat containing 15 (LRRC15), a member of the Leucine-rich repeat (LRRC) superfamily, is a type I transmembrane protein encoded on chromosome 3q2910. This protein is pivotal in cellular processes, predominantly through its involvement in protein–protein and protein–matrix11, 12. Recent studies have revealed the antiviral properties of LRRC15, which not only inhibits adenovirus infection but also prevents entry of the  \n1Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, China. 2Department of Medical Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, China. 3Departme","cbCaidmcqGh34zhr","https://ap.wps.com/l/cbCaidmcqGh34zhr","pdf",9319779,17,"English","# Introduction\n## Background on TNBC and unmet need\n## LRRC15 in cancer biology\n# Results\n## LRRC15 overexpression in TNBC\n# Methods and Mechanistic Insights\n## LRRC15 knockdown and functional effects\n## ITGB1/FAK/PI3K signalling pathway","[{\"question\":\"What role does LRRC15 play in triple-negative breast cancer?\",\"answer\":\"LRRC15 is highly overexpressed in TNBC and correlates with worse patient outcomes. Functionally, reducing LRRC15 suppresses TNBC cell proliferation, invasion, and migration in vitro and in vivo.\"},{\"question\":\"How does LRRC15 influence ITGB1 and downstream signalling?\",\"answer\":\"LRRC15 interacts with ITGB1, facilitates ITGB1 phosphorylation at the T788/T789 residues, and recruits FAK to integrin clusters. This leads to phosphorylation events that activate the PI3K/AKT pathway.\"},{\"question\":\"Why is targeting LRRC15 considered a therapeutic opportunity for TNBC?\",\"answer\":\"Because LRRC15 promotes TNBC proliferation and metastasis via the ITGB1/FAK/PI3K signalling pathway, it represents a promising candidate for therapeutic intervention aimed at disrupting this pro-tumour signalling axis.\"}]","Leucine rich repeat containing 15 promotes triple-negative breast cancer proliferation and invasion via the ITGB1/FAK/PI3K signalling pathway | PDF",1790182618,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bacc0a4f0a1e2d8034b23bd50fe780c5.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f05f1a9e9f16812b30919af5374354e1.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/912b85525c9eb155a40d59f7f55eefaf.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18312111d8787926ef06d12b7f8a6810.webp",980,1287]